Evidence map›Paper›PMID 35431912›Full record

ArticleFrontiers in pharmacology2021

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.

Roberta Murphy, Hannes Kettner, Rick Zeifman, Bruna Giribaldi, Laura Kartner, Jonny Martell, Tim Read, Ashleigh Murphy-Beiner, Michelle Baker-Jones, David Nutt and 3 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06303739 (Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression), which is not on this map. Cited by 87 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 9 pooled it
36.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06303739 phase3active not recruitingnot on this mapstarted 2024, after this paper: background citation

Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2024 to 2027Enrolled20ConditionsRefractory Depression, Treatment Resistant DepressionArmspsilocybin
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 9 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.Journal of psychopharmacology (Oxford, England) · 2025
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Psychedelics and the 'inner healer': Myth or mechanism?Journal of psychopharmacology (Oxford, England) · 2024
    Trial
  15. Trial
  16. Trial
  17. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Trial
  18. Article
  19. Review
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Roberta MurphyDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Hannes KettnerDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Rick ZeifmanDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Bruna GiribaldiDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Laura KartnerDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Jonny MartellDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Tim ReadDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Ashleigh Murphy-BeinerDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Michelle Baker-JonesDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
David NuttDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
David ErritzoeDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Rosalind WattsDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Robin Carhart-HarrisDepartment of Brain Sciences, Centre for Psychedelic Research, Imperial College London, Faculty of Medicine, London, United Kingdom.
Imperial College London · GBDevon Partnership NHS Trust · GBRoyal Holloway University of London · GBSouth West London and St George's Mental Health NHS Trust · GBToronto Metropolitan University · CAUniversity of California System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acute psychedelic experiencedepressionemotional breakthroughmystical experiencepsilocybinpsychedelic assisted therapytherapeutic alliancetherapeutic relationship

Identifiers

PMID35431912
PMCPMC9009076
OpenAlexW4221001769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.